# G. Kees Hovingh

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/g-kees-hovingh/

## Facts

| Field | Value |
| --- | --- |
| Citations | 33,163 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 76 |
| i10-index | 208 |
| Last Known Institution | Novo Nordisk (Denmark) |
| OpenAlex ID | https://openalex.org/A5004099465 |
| ORCID iD | https://orcid.org/0000-0002-8145-1676 |
| Works | 336 |

## Researcher papers

- [Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes](https://scholariq.org/papers/semaglutide-and-cardiovascular-outcomes-in-obesity-without-diabetes/)
- [Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity](https://scholariq.org/papers/semaglutide-in-patients-with-heart-failure-with-preserved-ejection-fraction-and/)
- [Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management](https://scholariq.org/papers/statin-associated-muscle-symptoms-impact-on-statin-therapy-european/)
- [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society](https://scholariq.org/papers/homozygous-familial-hypercholesterolaemia-new-insights-and-guidance-for/)
- [IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial](https://scholariq.org/papers/il-6-inhibition-with-ziltivekimab-in-patients-at-high-atherosclerotic-risk/)
- [Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes](https://scholariq.org/papers/semaglutide-in-patients-with-obesity-related-heart-failure-and-type-2-diabetes/)
- [Position paper Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel](https://scholariq.org/papers/position-paper-statin-intolerance-an-attempt-at-a-unified-definition-position/)
- [Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes](https://scholariq.org/papers/oral-semaglutide-and-cardiovascular-outcomes-in-high-risk-type-2-diabetes/)
- [Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial](https://scholariq.org/papers/long-term-weight-loss-effects-of-semaglutide-in-obesity-without-diabetes-in-the/)
- [Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)](https://scholariq.org/papers/global-perspective-of-familial-hypercholesterolaemia-a-cross-sectional-study/)
- [Gene-centric Meta-analysis in 87,736 Individuals of European Ancestry Identifies Multiple Blood-Pressure-Related Loci](https://scholariq.org/papers/gene-centric-meta-analysis-in-87-736-individuals-of-european-ancestry-identifies/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Diabetes, Cardiovascular Risks, and Lipoproteins](https://scholariq.org/topics/diabetes-cardiovascular-risks-and-lipoproteins/)
- [Cholesterol and Lipid Metabolism](https://scholariq.org/topics/cholesterol-and-lipid-metabolism/)
- [Cancer, Lipids, and Metabolism](https://scholariq.org/topics/cancer-lipids-and-metabolism/)
- [Genetic Associations and Epidemiology](https://scholariq.org/topics/genetic-associations-and-epidemiology/)

## Researcher university

- [Novo Nordisk (Denmark)](https://scholariq.org/institutions/novo-nordisk-denmark/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.